» Articles » PMID: 23256077

Theranostic Magnetic Resonance Imaging of Type 1 Diabetes and Pancreatic Islet Transplantation

Overview
Specialty Radiology
Date 2012 Dec 21
PMID 23256077
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes mellitus results in impaired insulin production by pancreatic islets due to autoimmunity. Islet transplantation has recently emerged as a promising treatment for this disease. To visualize and monitor endogenous and transplanted islets, non-invasive strategies are currently being developed. These include strategies for in vivo magnetic resonance imaging of microvascular changes during diabetes development, tracking the recruitment of diabetogenic T cells to the pancreas, and imaging of endogenous and transplanted islet mass. The combination of MR imaging agents with therapy is a novel state-of-the-art theranostic approach that has a tremendous potential for type 1 diabetes management. Though still in its infancy, theranostic MR imaging has shown certain encouraging progress. Here we provide an overview of the latest accomplishments in this area as it applies to changes in islet vasculature during diabetes development, monitoring autoimmune attack mediated by T cells, and imaging of transplanted islets. Future challenges and opportunities in the area of theranostic MRI are discussed as well.

Citing Articles

Brown Adipose Tissue as a Unique Niche for Islet Organoid Transplantation: Insights From In Vivo Imaging.

Sun A, Hayat H, Kenyon E, Quadri T, Amos D, Perkins K Transplant Direct. 2024; 10(7):e1658.

PMID: 38881741 PMC: 11177823. DOI: 10.1097/TXD.0000000000001658.


Targeted delivery of harmine to xenografted human pancreatic islets promotes robust cell proliferation.

Mishra S, Streeter P Sci Rep. 2022; 12(1):19127.

PMID: 36351917 PMC: 9646720. DOI: 10.1038/s41598-022-19453-5.


Molecular imaging of β-cells: diabetes and beyond.

Wei W, Ehlerding E, Lan X, Luo Q, Cai W Adv Drug Deliv Rev. 2019; 139:16-31.

PMID: 31378283 PMC: 6686871. DOI: 10.1016/j.addr.2018.06.022.


Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer.

Yildiz T, Gu R, Zauscher S, Betancourt T Int J Nanomedicine. 2018; 13:6961-6986.

PMID: 30464453 PMC: 6217908. DOI: 10.2147/IJN.S174068.


Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes.

Paredes-Juarez G, de Vos P, Bulte J Expert Rev Precis Med Drug Dev. 2017; 2(1):57-67.

PMID: 29276781 PMC: 5737787. DOI: 10.1080/23808993.2017.1302305.


References
1.
Caldorera-Moore M, Liechty W, Peppas N . Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res. 2011; 44(10):1061-70. PMC: 3219056. DOI: 10.1021/ar2001777. View

2.
Papaccio G . Insulitis and islet microvasculature in type 1 diabetes. Histol Histopathol. 1993; 8(4):751-9. View

3.
Bouckenooghe T, Flamez D, Ortis F, Goldman S, Eizirik D . Identification of new pancreatic beta cell targets for in vivo imaging by a systems biology approach. Curr Pharm Des. 2010; 16(14):1609-18. DOI: 10.2174/138161210791164117. View

4.
Issa C, Azar S . Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Curr Diab Rep. 2012; 12(5):560-7. DOI: 10.1007/s11892-012-0291-6. View

5.
Wang P, Yigit M, Ran C, Ross A, Wei L, Dai G . A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection. Diabetes. 2012; 61(12):3247-54. PMC: 3501867. DOI: 10.2337/db12-0441. View